Tag: Cancer: Breast

Approval is targeted for patients with HER2-low or HER2-ultralow metastatic breast cancer with disease progression after endocrine therapy

Approval is for those who have had prior therapy for unresectable or metastatic disease

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer

Superior breast cancer detection rate seen compared with standard double-reading, without negatively affecting recall rate

Compared with weight maintainers, increased risk seen for 5 to 10 percent and >10 percent weight gain

Decrease consistent with decreasing use of screening mammography since 2009 guideline change

For female patients aged at least 66 years, odds of prevalent CVD up with locally advanced and metastatic disease

Significant association seen for older age with increased risk for developing mastectomy skin flap/nipple necrosis, infection, seroma

Biennial screening rates lower among non-Hispanic women with other race, lesbian and bisexual women, rural residents

CBD did not meet primary end point comparing preingestion to postingestion anxiety, but resulted in lower anxiety levels